8-K/A: Exagen Inc. Appoints New CFO, Jeffrey Black, Effective September 1, 2024

Exagen Inc. has appointed Jeffrey Black as its new Chief Financial Officer, effective September 1, 2024, while also naming John Aballi as Interim CFO.

Summary

• Exagen Inc. has announced the appointment of Jeffrey Black as the new Chief Financial Officer (CFO), effective September 1, 2024.
• Mr. Black will receive an annual base salary of $460,000, a $125,000 signing bonus, and a potential annual performance bonus of up to 50% of his base salary.
• He will also be granted restricted stock units representing up to 225,000 shares of common stock, vesting over four years.
• Prior to Mr. Black's start date, John Aballi has been appointed as Interim CFO, effective August 1, 2024, replacing Kamal Adawi.
• Mr. Adawi's departure is effective August 1, 2024, and he will receive severance benefits as a Tier 2 participant under the company's severance plan.
• The company has filed an amended 8-K to correct the signature page of a prior filing and the effective date of Mr. Adawi's termination.

Sentiment

Score: 7

Explanation: The document reflects a positive change with the appointment of a new CFO, but also includes the departure of the previous CFO, which introduces some uncertainty. The overall sentiment is moderately positive.

Positives

• The appointment of a new CFO with extensive experience in publicly traded medical technology companies is a positive step for Exagen.
• The company has secured a seasoned financial executive with a strong background in the healthcare sector.
• The interim CFO appointment ensures a smooth transition while the new CFO prepares to take over.

Negatives

• The departure of the previous CFO, Kamal Adawi, may create some short-term uncertainty.
• The company is incurring costs associated with the severance package for the outgoing CFO and the signing bonus for the new CFO.

Risks

• The transition period with an interim CFO could pose some operational risks.
• The new CFO's performance and integration into the company will be critical for future financial stability.
• There is a risk that the new CFO's compensation package may be seen as excessive by some stakeholders.

Future Outlook

The company is focused on ensuring a smooth transition of financial leadership with the appointment of a new CFO and an interim CFO.

Management Comments

• The company announced the executive transition in a press release on August 1, 2024.
• The company has entered into an employment agreement with Jeffrey Black.

Industry Context

The appointment of a new CFO is a common occurrence in the corporate world, especially in publicly traded companies. Exagen's move to bring in a seasoned executive from the medical technology sector aligns with industry trends of seeking experienced financial leadership.

Comparison to Industry Standards

• The compensation package for Jeffrey Black, including a base salary of $460,000, a signing bonus of $125,000, and potential performance bonuses, is within the typical range for CFOs in publicly traded companies of similar size and industry.
• The vesting schedule for the restricted stock units, with 25% vesting annually over four years, is a standard practice in executive compensation.
• Companies like Standard BioTools Inc., Apollo Endosurgery Inc., and Alphatec Holdings, Inc., where Mr. Black previously held CFO positions, are comparable in terms of industry and market capitalization, suggesting that his experience is relevant to Exagen's needs.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CFO as a positive step towards financial stability and growth.
• Employees may experience changes in leadership and reporting structures within the finance department.
• Customers and suppliers are unlikely to be directly impacted by this executive change.

Next Steps

• Jeffrey Black will commence his role as CFO on September 1, 2024.
• John Aballi will serve as Interim CFO until September 1, 2024.
• The company will continue to operate under the leadership of the new and interim CFOs.

Key Dates

Keywords

Chief Financial Officer, CFO, Executive Appointment, Financial Officer, Interim CFO, Severance, Compensation, Restricted Stock Units, Medical Technology, Exagen Inc.